Thank you for reading this post, don't forget to subscribe!
Humira is one of the best promoteing drug of all time. And as biosimilars for the drug venture onto the open market in Jan. 2023, one of many large three PBMs is making room for the biosimilars to compete on equal footing with the brand-name version.
UnitedWell being Group’s PBM OptumRx — one of many largest within the US together with CVS Well being and Express Scripts — signaled Tuesday that it’ll place three biosimilars for the AbbVie-made drug gross sales king on its formulary, its preferred listing of medication, at parity with Humira, allowing biosimilars to compete on the identical tier because the drug itself.
Amgen is expected to launch the primary biosimilar to compete with Humira early subsequent 12 months and would be the first added to the formulary.
Humira was first approved by the FDA in 2002 for rheumatoid arthritis, including new indications through the years and rising to become essentially the most profitable drug ever, hauling in between $15 billion and $20 billion in gross sales per 12 months.
Beginning in January, with the entrance of Amgen’s biosimilar, AbbVie must fend off competition from Samsung, Boehringer Ingelheim, Viatris, and Sandoz, that are launching their versions of adalimumab subsequent June and July.
AbbVie has signaled that it expects about 45% erosion (+/-10%) of its Humira franchise in 2023, after seeing gross sales similarly plummet within the EU when biosimilars launched there 4 years in the past. AbbVie management also previously indicated that interchangein a position biosimilars (a designation Boehringer’s biosimilar alprepared has) can have some impact on pricing as two interchangein a position biosimilars have been baked into AbbVie’s guidance.
AbbVie didn’t respond to a request for comment from Finishfactors Information on the OptumRx transfer.
OptumRx will look to create much more competition for biosimilars, given Humira’s listing value of $70,000 a 12 months per patient, and studies presenting biosimilars are as protected and effective as Humira — effectively an equivalent at an affordableer value. And given OptumRx’s clout as each one of many largest PBMs within the US and the subsidiary of well being insurance supplier UnitedWell beingcare, others might follow.
During a session on Tuesday on the HLTH Conference in Las Vefuel, OptumRx CEO Heather Cianfrocco stated that the aim is to make a dent in rising specialty drug prices, including that “there may be extra to be executed.”